Critical appraisal of the role of davunetide in the treatment of progressive supranuclear palsy
Open Access
- 1 February 2012
- journal article
- expert opinion
- Published by Informa UK Limited in Neuropsychiatric Disease and Treatment
- Vol. 8, 85-93
- https://doi.org/10.2147/ndt.s12518
Abstract
Abstract: Progressive supranuclear palsy (PSP) is a rare neurodegenerative disease characterized by the accumulation of tau protein aggregates in the basal ganglia, brainstem and cerebral cortex leading to rapid disease progression and death. The neurofibrillary tangles that define the neuropathology of PSP are comprised of aggregated 4R tau and show a well-defined distribution. Classically, PSP is diagnosed by symptoms that include progressive gait disturbance, early falls, vertical ophthalmoparesis, akinetic-rigid features, prominent bulbar dysfunction and fronto-subcortical dementia. There are currently no effective therapies for the treatment of this rapidly degenerating and debilitating disease. Davunetide is a novel neuroprotective peptide that is thought to impact neuronal integrity and cell survival through the stabilization of microtubules. Preclinical activity in models of tauopathy has been translated to clinical studies, demonstrating pharmacologic activity that has supported further development. Davunetide's efficacy and tolerability are being tested in a placebo-controlled study in PSP patients, making it the most advanced drug candidate in this indication. This review examines the disease characteristics of PSP, the rationale for treating PSP with davunetide and assesses some of the challenges of clinical trials in this patient population.Keywords
This publication has 61 references indexed in Scilit:
- Disease Severity and Progression in Progressive Supranuclear Palsy and Multiple System Atrophy: Validation of the NNIPPS – PARKINSON PLUS SCALEPLOS ONE, 2011
- The Many Faces of TauNeuron, 2011
- A pilot trial of the microtubule-interacting peptide (NAP) in mice overexpressing alpha-synuclein shows improvement in motor function and reduction of alpha-synuclein inclusionsMolecular and Cellular Neuroscience, 2011
- Selective frontal neurodegeneration of the inferior fronto-occipital fasciculus in progressive supranuclear palsy (PSP) demonstrated by diffusion tensor tractographyBMC Neurology, 2011
- Strategies for diminishing katanin-based loss of microtubules in tauopathic neurodegenerative diseasesHuman Molecular Genetics, 2010
- Tauopathies with parkinsonism: clinical spectrum, neuropathologic basis, biological markers, and treatment optionsEuropean Journal of Neurology, 2009
- Ethanol inhibits neuronal differentiation by disrupting activity-dependent neuroprotective protein signalingProceedings of the National Academy of Sciences of the United States of America, 2008
- Riluzole treatment, survival and diagnostic criteria in Parkinson plus disorders: The NNIPPS StudyBrain, 2008
- Activity-dependent neuroprotective protein (ADNP) differentially interacts with chromatin to regulate genes essential for embryogenesisDevelopmental Biology, 2007
- Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome)Neurology, 1996